An Open-Label, Single-Arm, Prospective Interventional Study on Anti-Resistance Therapy for Patients with Third-Generation EGFR-TKI-Resistant Lung Cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500101720

Enrollment

Unknown

Registered

2025-04-29

Start date

2025-05-01

Completion date

Unknown

Last updated

2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Intervention group:Third-Generation EGFR-TKIs in Combination with Baicalin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who relapsed following third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.

Exclusion criteria

Exclusion criteria: Patients with low treatment tolerance and poor adherence to therapy.

Design outcomes

Primary

Measure	Time frame
Objective response rate;	—

Secondary

Measure	Time frame
Disease control rate;Clinical benefit rate;Progression free survival;1 year overall survival;	—

Countries

China

Contacts

Public ContactXueying Yang

The Fourth Affiliated Hospital of China Medical University

yangxueying@cmu.edu.cn+86 189 0401 9778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026